Full analysis of the effects and effects of cabergoline

Cabergoline is a dopamine D2 receptor agonist drug widely used clinically. It is mainly used to treat a series of endocrine disorders caused by abnormally elevated levels of prolactin (prolactin) in the body. Its pharmacological mechanism mainly inhibits the synthesis and release of prolactin in the anterior pituitary gland by simulating the action of dopamine, thereby helping to restore hormone balance in the body. This drug has shown unique efficacy in the treatment of hyperprolactinemia (HPRL), pituitary prolactinoma and other diseases. It is especially favored clinically for its long half-life and good tolerance.

In terms of hyperprolactinemia, the application of cabergoline can effectively reduce serum prolactin levels, thereby improving symptoms such as irregular menstruation, amenorrhea, infertility and abnormal lactation in women caused by it. In male patients, the drug can also reverse testosterone decline, sexual dysfunction, and abnormal sperm production caused by high prolactin. Since elevated prolactin levels may also inhibit hypothalamic-pituitary-gonadal axis function, the clinical significance of cabergoline in improving reproductive system function by intervening in this mechanism cannot be ignored.

Additionally, in the treatment of pituitary microadenomas or prolactin adenomas, cabergoline not only helps control hormone levels but has also been found to reduce tumor size. Through long-term regular use, many patients can achieve significant reduction in tumor size or even disappearance. This discovery broadens the application boundaries of cabergoline in neuroendocrine lesions.

Cabergoline also occupies a certain position in the drug combination treatment of Parkinson's disease. Although its application in this area has been relatively reduced in recent years, it still has a certain auxiliary effect in controlling symptoms such as tremor and muscle stiffness. Due to its strong agonistic effect on dopamine receptors, some countries are still conducting follow-up research on its use in neurodegenerative diseases.

Reference materials:https://www.drugs.com/mtm/cabergoline.html